Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 13/20 | 0.70 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792342 | 0.95 | HCRTR1 (0.78) | HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL6789132 | 0.95 | HCRTR1 (0.78) | HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL6788648 | 0.90 | HCRTR1 (0.74) | HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL6788500 | 0.90 | HCRTR1 (0.77) | HCRTR1HCRTR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL6789122 | 0.88 | HCRTR1 (0.90) | HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL4430693 | 0.88 | HCRTR1 (0.90) | HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL6787154 | 0.85 | HCRTR1 (0.81) | HCRTR1HCRTR2 | |
| SCHEMBL6787308 | 0.85 | HCRTR1 (0.84) | HCRTR1HCRTR2 | |
| SCHEMBL6795294 | 0.85 | HCRTR1 (0.91) | HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL6789681 | 0.84 | HCRTR1 (0.59) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703392-B2 | OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-09 | — | — | US | disclosed |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2003-09-18 | — | — | US | disclosed |
| EP-1274687-A1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001068609-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885SMN1; SMN2 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.